European journal of ophthalmology · 2012
Triple therapy for corneal neovascularization: a case report.
Клинический случайСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Veritti Daniele, Vergallo Stefano, Lanzetta Paolo
Аннотация
PURPOSE: To investigate the effect of the combination of photodynamic therapy with verteporfin and subconjunctival bevacizumab and triamcinolone acetonide on corneal neovascularization secondary to corneal graft failure.
METHODS: A patient with extensive deep and superficial corneal neovascularization underwent same day triple therapy with subconjunctival bevacizumab (1.25 mg), subconjunctival triamcinolone acetonide (40 mg), and photodynamic therapy with verteporfin (fluence 50 J/cm², irradiance 300 mW/cm²).
RESULTS: A complete angiographic new vessel regression was obtained and was discernible starting 7 days after combination therapy. Three months after treatment, an initial new-vessel sprout was noted. Triple therapy was then repeated. No angiographic evidence of corneal neovascularization was detectable for the entire 6-month follow-up duration.
CONCLUSIONS: Triple therapy may offer a promising tool in the treatment of corneal neovascularization.
METHODS: A patient with extensive deep and superficial corneal neovascularization underwent same day triple therapy with subconjunctival bevacizumab (1.25 mg), subconjunctival triamcinolone acetonide (40 mg), and photodynamic therapy with verteporfin (fluence 50 J/cm², irradiance 300 mW/cm²).
RESULTS: A complete angiographic new vessel regression was obtained and was discernible starting 7 days after combination therapy. Three months after treatment, an initial new-vessel sprout was noted. Triple therapy was then repeated. No angiographic evidence of corneal neovascularization was detectable for the entire 6-month follow-up duration.
CONCLUSIONS: Triple therapy may offer a promising tool in the treatment of corneal neovascularization.
Предметные рубрики MeSH
AgedAngiogenesis InhibitorsAntibodies, Monoclonal, HumanizedBevacizumabCombined Modality TherapyCorneal NeovascularizationDrug Therapy, CombinationFluorescein AngiographyGlucocorticoidsGraft RejectionHumansMalePhotochemotherapyPhotosensitizing AgentsPorphyrinsTriamcinolone AcetonideVerteporfinVisual Acuity